CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer

SABCS 2017
Videos

Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer.

Related Items

Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Final Results of NeoMONARCH: A Phase 2 Neoadjuvant Study of Abemaciclib in Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
A Phase 1b Study of Abemaciclib plus Pembrolizumab for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
US Treatment Patterns for Young Women with HR-Positive, HER2-Negative Metastatic Breast Cancer in the Era of CDK4/6 Inhibitors
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Phase 1-2 Trial of Pembrolizumab and Either Doxorubicin or an Aromatase Inhibitor for Triple-Negative or HR-Positive Metastatic Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Abemaciclib plus Standard Adjuvant ET versus Standard Adjuvant ET Alone in High-Risk Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Abemaciclib for the Treatment of Brain Metastases Secondary to HR-Positive Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
The Synergistic Antitumor Activity of Entinostat (MS-275) in Combination with Palbociclib (PD 0332991) in ER-Positive and TN Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
The Benefit of Abemaciclib in Prognostic Subgroups: An Exploratory Analysis of Combined Data from MONARCH 2 and 3
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Phase 2 Study of the Feasibility and Safety of Radium-223 Dichloride plus Hormonal Therapy and Denosumab for the Treatment of HR-Positive Breast Cancer with Bone-Dominant Metastasis
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications

© Amplity Health. All Rights Reserved. Privacy Policy